Barylski M, et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy: A meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013; 72:35–44.
Haas ME, et al. The role of proprotein convertase subtilisin/kexin type 9 in nephrotic syndrome-associated hypercholesterolemia. Circulation 2016; 134:61–72.
Farnier M, et al. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY phase 3 clinical program trials. Int J Cardiol 2016; 223:750–757.
Sabatine MS, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376:1713–1722.
Toth PP, et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int 2018; 93:1397–1408.